Boston Partners reduced its stake in Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) by 44.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,750 shares of the company's stock after selling 35,203 shares during the period. Boston Partners owned approximately 0.11% of Viemed Healthcare worth $351,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the stock. National Bank of Canada FI lifted its holdings in Viemed Healthcare by 91.2% during the 3rd quarter. National Bank of Canada FI now owns 3,346 shares of the company's stock worth $25,000 after purchasing an additional 1,596 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Viemed Healthcare in the fourth quarter worth about $41,000. PDT Partners LLC bought a new position in shares of Viemed Healthcare in the third quarter valued at approximately $78,000. Walleye Capital LLC purchased a new stake in Viemed Healthcare in the 3rd quarter worth approximately $87,000. Finally, BBR Partners LLC bought a new stake in Viemed Healthcare during the third quarter valued at $110,000. 74.24% of the stock is currently owned by hedge funds and other institutional investors.
Viemed Healthcare Price Performance
Viemed Healthcare stock traded up $0.05 during mid-day trading on Thursday, hitting $7.25. 124,151 shares of the company traded hands, compared to its average volume of 133,367. Viemed Healthcare, Inc. has a one year low of $6.21 and a one year high of $9.81. The stock has a fifty day moving average price of $7.86 and a 200-day moving average price of $8.19. The stock has a market cap of $286.53 million, a price-to-earnings ratio of 26.85 and a beta of 1.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.19 and a current ratio of 1.31.
Viemed Healthcare Profile
(
Free Report)
Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Featured Stories
Before you consider Viemed Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viemed Healthcare wasn't on the list.
While Viemed Healthcare currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
